☆ 4.7 Editorial Material

Quantitation of Hemoglobin Improves Fecal Immunochemical Tests for Noninvasive Screening

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2013)

Journal

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY

Volume 11, Issue 7, Pages 839-840

Publisher

ELSEVIER SCIENCE INC

DOI: 10.1016/j.cgh.2013.02.031

Keywords

-

Categories

Gastroenterology & Hepatology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Review Medical Laboratory Technology

Noninvasive fecal testing for colorectal cancer

Jianhua Zou, Zhanshuo Xiao, Yu Wu, Jingyan Yang, Ning Cui

Summary: This review discusses the utility of stool diagnostic biomarkers for colorectal cancer (CRC) screening. The multitarget stool DNA test (MT-sDNA) is found to be the most sensitive test for CRC, although it comes with a high cost. MicroRNAs, protein biomarkers, and microbiota have the potential to be used as CRC screening tools, but further research is needed.

CLINICA CHIMICA ACTA (2022)

Add to Collection

Article Oncology

Fecal Immunochemical Tests Detect Screening Participants with Multiple Advanced Adenomas Better than T1 Colorectal Cancers

Anton Gies, Tobias Niedermaier, Laura Fiona Gruner, Thomas Heisser, Petra Schrotz-King, Hermann Brenner

Summary: FOBTs show lower sensitivities in detecting early-stage colorectal cancer, particularly T1 cancers. Further research should focus on improving the detection of early-stage cancer.

CANCERS (2021)

Add to Collection

Article Gastroenterology & Hepatology

Impact on healthcare resources of switch from fecal occult blood test to fecal immunochemical test within the English Bowel Cancer Screening Program: a single-center study

Stavroula Pelitari, Abhirami Gautham, Pritesh Mistry, Siddhartha Mohan, Matthew Brookes, Brian McKaig, Ashit Shah, Sarah Jewes, Gemma Fieldhouse, Andrew Veitch, Aravinth Murugananthan

Summary: The implementation of FIT in the Bowel Cancer Screening Program in England led to higher return and sample positivity rates compared to the previous FOBT. Patients in the FIT group required more endoscopic procedures, SSP time, radiology tests, and surgical procedures, resulting in considerable ongoing financial costs. The increase in services also had implications on histopathology services, with FIT leading to more histology samples and a higher number of polyps found per patient.

GASTROINTESTINAL ENDOSCOPY (2021)

Add to Collection

Article Gastroenterology & Hepatology

Fecal MicroRNA-Based Algorithm Increases Effectiveness of Fecal Immunochemical Test-Based Screening for Colorectal Cancer

Saray Duran-Sanchon, Lorena Moreno, Javier Gomez-Matas, Josep M. Auge, Miquel Serra-Burriel, Miriam Cuatrecasas, Leticia Moreira, Anna Serradesanferm, Angels Pozo, Jaume Grau, Maria Pellise, Meritxell Gironella, Antoni Castells

Summary: The miRFec algorithm can effectively identify individuals at highest risk for advanced colorectal neoplasia and differentiate patients with colorectal cancer from those with non-advanced adenomas or normal colonoscopy. By incorporating this algorithm, 34% of colonoscopies could be avoided, increasing the effectiveness and efficiency of FIT-based CRC screening programs.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2021)

Add to Collection

Review Gastroenterology & Hepatology

Emerging Tests for Noninvasive Colorectal Cancer Screening

Marina Hanna, Neelendu Dey, William M. Grady

Summary: Colorectal cancer is a common cancer globally and is a leading cause of cancer-related deaths. Current screening methods for colorectal cancer have limitations and many people are not compliant with screening recommendations. Novel screening tests based on advances in molecular biology, genetics, and epigenetics, as well as sequencing technologies and computational analytic methods, have been developed to improve early detection of colorectal cancer.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2023)

Add to Collection

Article Gastroenterology & Hepatology

Both fecal calprotectin and fecal immunochemical tests are useful in children with inflammatory bowel disease

Hirotaka Shimizu, Ryo Ebana, Takahiro Kudo, Takuro Sato, Tomoko Hara, Kenji Hosoi, Masaaki Usami, Masashi Yoshida, Ichiro Takeuchi, Hiroshi Nakase, Itaru Iwama, Katsuhiro Arai, Toshiaki Shimizu

Summary: Fecal calprotectin (FCP) and fecal immunochemical test (FIT) correlate well with endoscopic activity in pediatric patients with inflammatory bowel disease (IBD), and FCP is a superior marker for predicting mucosal healing (MH).

JOURNAL OF GASTROENTEROLOGY (2022)

Add to Collection

Article Multidisciplinary Sciences

Reusing a prepaid health plan's fecal immunochemical tests for microbiome associations with colorectal adenoma

James J. Goedert, Zhenyi Wu, Cyndee H. Yonehara, Timothy B. Frankland, Rashmi Sinha, Gieira S. Jones, Yunhu Wan, Jacques Ravel, Ni Zhao, Stacey A. Honda

Summary: This study used FIT samples to analyze the fecal microbiome and found no consistent association between CRA/CRC and fecal microbiome diversity or composition. Men had a higher risk of being FIT positive. The findings of this study have important implications for future microbiome research design and sample size determination.

SCIENTIFIC REPORTS (2022)

Add to Collection

Article Pharmacology & Pharmacy

Combining the Fecal Immunochemical Test with a Logistic Regression Model for Screening Colorectal Neoplasia

Feiyuan Liu, Qiaoyun Long, Hui He, Shaowei Dong, Li Zhao, Chang Zou, Weiqing Wu

Summary: In this study, a classifier model was established by combining FIT results and other demographic and clinical features to enhance the sensitivity of identifying colorectal neoplasia. The top six features mostly related to CRC include age, gender, history of intestinal adenoma or polyposis, smoking history, gastrointestinal discomfort symptom, and fruit eating habit. The LR algorithm was used to generate the model, achieving an AUC score of 0.92 and an NMSE score of 0.076 in separating normal individuals from participants with colorectal neoplasia.

FRONTIERS IN PHARMACOLOGY (2021)

Add to Collection

Article Gastroenterology & Hepatology

Increased Colorectal Cancer Screening Sustained with Mailed Fecal Immunochemical Test Outreach

Briton Lee, Erin Keyes, Carly Rachocki, Barbara Grimes, Ellen Chen, Eric Vittinghoff, Uri Ladabaum, Ma Somsouk

Summary: The mailed FIT program significantly increased colorectal cancer screening over multiple years. Patients in the intervention group were more likely to complete the FIT and had a longer duration of screening. However, the completion rate in the second intervention cycle was lower for patients who did not complete the FIT in the first cycle.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2022)

Add to Collection

Article Public, Environmental & Occupational Health

Cost-effectiveness analysis of colonoscopy and fecal immunochemical testing for colorectal cancer screening in China

Yinan Ren, Mingye Zhao, Dachuang Zhou, Qian Xing, Fangfang Gong, Wenxi Tang

Summary: This study evaluated the cost-effectiveness of colorectal cancer screening in China and found that FIT screening can save costs, while colonoscopy is cost-effective. In specific regions, high-income areas could consider strategies with more frequent electronic colonoscopy.

FRONTIERS IN PUBLIC HEALTH (2022)

Add to Collection

Article Oncology

The multitarget fecal immunochemical test versus the fecal immunochemical test for programmatic colorectal cancer screening: a cross-sectional intervention study with paired design

P. H. A. Wisse, W. de Klaver, F. van Wifferen, L. Meiqari, M. Bierkens, M. J. E. Greuter, B. Carvalho, M. E. van Leerdam, M. C. W. Spaander, E. Dekker, V. M. H. Coupe, M. de Wit, G. A. Meijer

Summary: This study aims to validate the relative sensitivity of mtFIT compared to FIT in colorectal cancer (CRC) screening, and predict the lifetime health effects and costs using the Adenoma and Serrated Pathway to Colorectal CAncer model. The results of this study will provide important clinical utility information for the Dutch national CRC screening program.

BMC CANCER (2022)

Add to Collection

Article Gastroenterology & Hepatology

Results of Compliant Participation in Five Rounds of Fecal Immunochemical Test Screening for Colorectal Cancer

Flavia Baldacchini, Lauro Bucchi, Orietta Giuliani, Silvia Mancini, Alessandra Ravaioli, Rosa Vattiato, Paolo Giorgi Rossi, Cinzia Campari, Debora Canuti, Enza Di Felice, Francesca Mezzetti, Priscilla Sassoli de Bianchi, Stefano Ferretti, Fabio Falcini

Summary: The study revealed a significant decrease in the proportion of men with a positive FIT result and detection rates of advanced adenoma between the second and third rounds of screening. There was a slight decrease in positive predictive values for advanced adenoma, CRC, and advanced neoplasia by the fourth and fifth rounds. These findings suggest that FIT screening can prevent the progression of some advanced adenomas, allowing for a risk-based screening strategy.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2021)

Add to Collection

Article Gastroenterology & Hepatology

Colorectal Cancer Stage Distribution at First and Repeat Fecal Immunochemical Test Screening

Arthur Kooyker, Lucie de Jonge, Esther Toes-Zoutendijk, Manon Spaander, Hanneke van Vuuren, Ernst Kuipers, Folkert van Kemenade, Chris Ramakers, Evelien Dekker, Iris Nagtegaal, Monique van Leerdam, Iris Lansdorp-Vogelaar

Summary: FIT-based screening is effective in detecting early-stage colorectal cancer, and this effectiveness is maintained even with repeat screening. Increasing the FIT cut-off value significantly reduces the number of detected cancers, but the majority of detected cancers are still diagnosed at an early stage.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2023)

Add to Collection

Article Gastroenterology & Hepatology

Multiple Negative Fecal Immunochemical Tests Reduce Risk of Advanced Neoplasia in a Colonoscopy Surveillance Program

Molla M. Wassie, Graeme P. Young, Jean M. Winter, Charles Cock, Peter Bampton, Mahadya Rahman, Richard Heddle, Robert Fraser, Rosie Meng, Erin L. Symonds

Summary: Multiple rounds of negative FIT are associated with a reduced risk of advanced neoplasia in above-average-risk individuals undergoing surveillance colonoscopy.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2023)

Add to Collection

Article Gastroenterology & Hepatology

Colonoscopy-Related Mortality in a Fecal Immunochemical Test-Based Colorectal Cancer Screening Program

Arthur I. Kooyker, Esther Toes-Zoutendijk, Annemieke W. J. Opstal-van Winden, Maaike Buskermolen, Hanneke J. van Vuuren, Ernst J. Kuipers, Folkert J. van Kemenade, Chris Ramakers, Evelien Dekker, Iris D. Nagtegaal, Harry J. de Koning, Manon C. W. Spaander, Iris Lansdorp-Vogelaar, Monique E. van Leerdam

Summary: The colonoscopy-related mortality within the Dutch FIT-based CRC screening program was estimated to range from 0.23 to 0.91 per 10,000 FIT-positive participants undergoing colonoscopy, with 50% of likely colonoscopy-related causes of death being cardiovascular events.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2021)

Add to Collection

Meeting Abstract Oncology

Assessment of methylated BCAT1 and IKZF1 circulating tumor DNA as a potential diagnostic and prognostic biomarker in esophagogastic cancers

Mei Mei Chan, Jean M. Winter, Susanne Kartin Pedersen, Amitesh Chandra Roy, David I. Watson, Damian Hussey, Graeme P. Young, Erin L. Symonds

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Meeting Abstract Oncology

Detection of circulating DNA methylated BCAT1 and IKZF1 in pancreatic adenocarcinoma

Jean M. Winter, Lorraine Sheehan-Hennessy, Susanne Kartin Pedersen, Graeme P. Young, Erin L. Symonds

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Oncology

Assessment of tumor burden and response to therapy in patients with colorectal cancer using a quantitative ctDNA test for methylated BCAT1/IKZF1

Erin L. Symonds, Susanne K. Pedersen, Bernita Yeo, Hiba Al Naji, Susan E. Byrne, Amitesh Roy, Graeme P. Young

Summary: This study assessed the use of BCAT1 and IKZF1 methylation levels to quantify circulating tumor DNA (ctDNA) in colorectal cancer patients. The results showed that ctDNA levels were correlated with disease progression, tumor diameter, and volume. After treatment, ctDNA levels decreased and the presence of ctDNA was associated with disease progression.

MOLECULAR ONCOLOGY (2022)

Add to Collection

Article Oncology

Detection of recurrent colorectal cancer with high specificity using a reporting threshold for circulating tumor DNA methylated in BCAT1 and IKZF1

Susanne K. Pedersen, Benjamin L. Musher, Lawrence C. LaPointe, Melissa K. Tuck, Erin L. Symonds, Naima Loayza, Graeme P. Young

Summary: Establishing an upper reference limit for the methylated BCAT1 and IKZF1 blood assay improved specificity for detecting CRC recurrence without compromising sensitivity. The BCAT1/IKZF1 test was more sensitive than CEA for identifying recurrences amenable to surgery with curative intent.

CANCER (2022)

Add to Collection

Article Oncology

Detection of hypermethylated BCAT1 and IKZF1 DNA in blood and tissues of colorectal, breast and prostate cancer patients

Jean M. Winter, Lorraine Sheehan-Hennessy, Beibei Yao, Susanne K. Pedersen, Molla M. Wassie, Michael Eaton, Michael Chong, Graeme P. Young, Erin L. Symonds

Summary: Detection of circulating DNA methylated in BCAT1 and IKZF1 is sensitive and specific for colorectal cancer, but not effective for breast or prostate cancer.

CANCER BIOMARKERS (2022)

Add to Collection

Review Oncology

Screening and risk reducing surgery for endometrial or ovarian cancers in Lynch syndrome: a systematic review

Natalie Lim, Martha Hickey, Graeme P. Young, Finlay A. Macrae, Christabel Kelly

Summary: There is limited evidence to support screening for endometrial and ovarian cancer in Lynch syndrome. Data on mortality reduction are not available. Further randomized trials comparing targeted screening methods are needed. Risk reducing surgery remains the most reliable way to reduce endometrial and ovarian cancer risk in Lynch syndrome.

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2022)

Add to Collection

Article Gastroenterology & Hepatology

Faecal immunochemical test mitigates risk of delayed colonoscopy in people with elevated risk of colorectal neoplasia

Molla M. Wassie, Graeme P. Young, Charles Cock, Peter Bampton, Jean M. Winter, Kalindra Simpson, Hariti Saluja, Anthony Chuang, Robert J. Fraser, Erin L. Symonds

Summary: Delayed surveillance colonoscopy may increase the risk of advanced neoplasia, particularly in individuals with prior advanced adenoma diagnosis, older age, and nonparticipation in interval FIT testing. However, colonoscopy delay does not seem to increase the risk in individuals with negative interval FIT results.

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2022)

Add to Collection

Review Medicine, General & Internal

Accuracy of blood-based biomarkers for screening precancerous colorectal lesions: a protocol for systematic review and meta-analysis

Timothy J. H. Lathlean, Molla M. Wassie, Jean M. Winter, Rishabh Goyal, Graeme P. Young, Erin L. Symonds

Summary: Colorectal cancer is the third most diagnosed cancer worldwide and is the second leading cause of cancer mortality. Current screening programs for colorectal cancer have low participation rates. This research aims to evaluate the accuracy of blood-based biomarker tests in detecting advanced precancerous lesions.

BMJ OPEN (2022)

Add to Collection

Article Oncology

Detection of methylated BCAT1 and IKZF1 after curative-intent treatment as a prognostic indicator for colorectal cancer recurrence

Susanne K. Pedersen, Erin L. Symonds, Amitesh C. Roy, Kathryn J. Cornthwaite, Lawrence C. LaPointe, Graeme P. Young

Summary: This study found that detection of methylated BCAT1 and IKZF1 after curative-intent treatment for colorectal cancer is significantly associated with an increased risk of recurrence and poorer recurrence-free survival. Patients with detectable methylated BCAT1 and IKZF1 may require personalized surveillance for better management.

CANCER MEDICINE (2023)

Add to Collection

Article Oncology

Patient attitudes towards changes in colorectal cancer surveillance: An application of the Health Belief Model

Maddison Dix, Carlene J. Wilson, Ingrid H. Flight, Molla M. Wassie, Graeme P. Young, Charles Cock, Sarah Cohen-Woods, Erin L. Symonds

Summary: This study aims to determine whether health beliefs regarding colorectal cancer (CRC) screening could predict discomfort with a change to CRC surveillance proposing regular faecal immunochemical tests (FIT) instead of colonoscopy. The results suggest that health beliefs and perceived threat of CRC should be considered when changing CRC surveillance protocols.

EUROPEAN JOURNAL OF CANCER CARE (2022)

Add to Collection

Article Gastroenterology & Hepatology

Multiple Negative Fecal Immunochemical Tests Reduce Risk of Advanced Neoplasia in a Colonoscopy Surveillance Program

Molla M. Wassie, Graeme P. Young, Jean M. Winter, Charles Cock, Peter Bampton, Mahadya Rahman, Richard Heddle, Robert Fraser, Rosie Meng, Erin L. Symonds

Summary: Multiple rounds of negative FIT are associated with a reduced risk of advanced neoplasia in above-average-risk individuals undergoing surveillance colonoscopy.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2023)

Add to Collection

Article Medical Laboratory Technology

Hot Mail: Temperature Exposure during Mail Return of an Immunochemical Fecal Occult Blood Test

Geraldine Laven-Law, Dawn Bastin, Robert J. L. Fraser, Charles Cock, Graeme P. Young, Jean M. Winter, Erin L. Symonds

Summary: This study aimed to determine the impact of high temperature on OC-Sensor FIT hemoglobin concentration and found that incubation at temperatures of 30 to 35 degrees Celsius reduced FIT hemoglobin concentration after more than 4 days. During mail transit, the maximum FIT temperature was on average 6.4 degrees Celsius above the maximum ambient temperature, but exposure to temperatures above 30 degrees Celsius was less than 24 hours. Data from a screening program showed no association between FIT hemoglobin concentration and maximum ambient temperatures.

CLINICAL CHEMISTRY (2023)

Add to Collection

Article Oncology

Health utility assessments in individuals undergoing diagnostic and surveillance colonoscopy: improved discrimination with a cancer-specific scale

Norma B. Bulamu, Gang Chen, Ellen Mcgrane, Charles Cock, Graeme P. Young, Erin L. Symonds

Summary: This study compares the sensitivity and discriminant validity of generic and cancer-specific measures for assessing health-related quality of life (HRQoL) for individuals undergoing diagnostic or surveillance colonoscopy for colorectal cancer. The results show that patients undergoing colonoscopy for symptoms have lower HRQoL compared to surveillance or positive FOBT. The cancer-specific QLU-C10D was found to be more sensitive and capable of distinguishing between patients undergoing colonoscopy for different indications.

CANCER CAUSES & CONTROL (2023)

Add to Collection

Article Gastroenterology & Hepatology

An efficient strategy for evaluating new non-invasive screening tests for colorectal cancer: the guiding principles

Robert S. Bresalier, Carlo Senore, Graeme P. Young, James Allison, Robert Benamouzig, Sally Benton, Patrick M. M. Bossuyt, Luis Caro, Beatriz Carvalho, Han-Mo Chiu, Veerle M. H. Coupe, Willemijn de Klaver, Clasine Maria de Klerk, Evelien Dekker, Sunil Dolwani, Callum G. Fraser, William Grady, Lydia Guittet, Samir Gupta, Stephen P. Halloran, Ulrike Haug, Geir Hoff, Steven Itzkowitz, Tim Kortlever, Anastasios Koulaouzidis, Uri Ladabaum, Beatrice Lauby-Secretan, Marcis Leja, Bernard Levin, Theodore Robert Levin, Finlay Macrae, Gerrit A. Meijer, Joshua Melson, Colm O'Morain, Susan Parry, Linda Rabeneck, David F. Ransohoff, Roque Saenz, Hiroshi Saito, Silvia Sanduleanu-Dascalescu, Robert E. Schoen, Kevin Selby, Harminder Singh, Robert J. C. Steele, Joseph J. Y. Sung, Erin Leigh Symonds, Sidney J. Winawer

Summary: New non-invasive tests for colorectal cancer (CRC) are emerging, making it challenging to conduct trials with mortality reduction as the main goal. A formal consensus approach involving experts resulted in the revision of previously established principles and the emergence of twelve new principles. The effectiveness of a new test can be evaluated by comparing it with an established non-invasive test, with the faecal immunochemical test considered as the appropriate comparator. Flexible adjustment of the new test's positivity threshold is desirable to meet different screening goals and requirements. A four-phased approach is proposed for the evaluation of new tests, including small studies, prospective estimation of accuracy, evaluation in screening populations, and monitoring for missed lesions.

GUT (2023)

Add to Collection

Article Gastroenterology & Hepatology

FIT for purpose: study protocol for a randomized controlled trial to personalize surveillance colonoscopy for individuals at elevated risk of colorectal cancer

Jean M. Winter, Kathryn J. Cornthwaite, Graeme P. Young, Carlene Wilson, Gang Chen, Richard Woodman, Michelle Coats, Robert Fraser, Charles Cock, Peter Bampton, Erin L. Symonds

Summary: The purpose of this study is to determine the safety, cost-effectiveness, and patient acceptance of extending colonoscopy surveillance intervals using the fecal immunochemical test (FIT) for individuals at elevated risk of colorectal cancer (CRC). Participants with a low FIT result will be randomized to either continue surveillance colonoscopy as scheduled or delay it by 1 or 2 years. The primary endpoint is the incidence of advanced neoplasia.

INTERNATIONAL JOURNAL OF COLORECTAL DISEASE (2023)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.